Semnur Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Semnur Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 2, 2024 | $50.00M | Apr 2, 2025 |
| FY2024 | Feb 22, 2024 | $50.00M | Apr 2, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.42M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | ($167.3K) | Apr 2, 2025 |
| FY2024 | Dec 31, 2023 | $632.5K | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($419.4K) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($160.42M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.69M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.17M) | Apr 2, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.71M | Feb 27, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.87M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.89M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($632.8K) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($426.1K) | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.68M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $50.69M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $86.28M | Apr 1, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $49.47M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $8.49M | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | $4.18M | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.75M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($42.78M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($38.09M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($3.27M) | Apr 2, 2025 |
| FY2022 | Jan 4, 2022 | $0 | Mar 17, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($275.80M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($115.38M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.28M) | Apr 2, 2025 |
| FY2023 | Dec 31, 2022 | ($3.27M) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $12.0K | Feb 27, 2026 |
| FY2023 | Dec 31, 2023 | $204.5K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $819.7K | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 230.21M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 200.00M | Feb 27, 2026 |